Cadila Healthcare share price adds 3% after getting approval from DCGI for Phase III clinical trials

Cadila Healthcare share price gained over 3% in the morning session on January 4 after the company received DCGI’ s approval to start Phase III clinical trials of its COVID-19 vaccine ZyCoV-D. At 09:23 AM IST, the share was trading at Rs 487.95, up by Rs 9.55, or 2% on the BSE. The share touched its 52-week high Rs 499 on December 28 and 52-week low Rs 212 March 13, 2020. It is trading 2.21% below its 52-week high and 129.4% above its 52-week low.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More